|
Black Diamond Therapeutics, Inc. (BDTX) DCF Valuation
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Black Diamond Therapeutics, Inc. (BDTX) Bundle
Designed for accuracy, our (BDTX) DCF Calculator enables you to assess the valuation of Black Diamond Therapeutics, Inc. using real-world financial data and provides complete flexibility to modify all key parameters for enhanced projections.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EBITDA | -29.3 | -66.7 | -126.7 | -92.3 | -86.0 | .0 | .0 | .0 | .0 | .0 |
EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Depreciation | .0 | .6 | 2.2 | 3.2 | .4 | .0 | .0 | .0 | .0 | .0 |
Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
EBIT | -29.3 | -67.3 | -128.9 | -95.6 | -86.5 | .0 | .0 | .0 | .0 | .0 |
EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Total Cash | 154.7 | 315.1 | 209.8 | 122.8 | 131.4 | .0 | .0 | .0 | .0 | .0 |
Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Accounts Payable | 2.0 | 2.5 | 4.1 | 1.9 | 2.3 | .0 | .0 | .0 | .0 | .0 |
Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Capital Expenditure | .0 | -.1 | -2.7 | -.2 | .0 | .0 | .0 | .0 | .0 | .0 |
Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EBITAT | -34.2 | -65.5 | -126.4 | -90.8 | -86.5 | .0 | .0 | .0 | .0 | .0 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -32.2 | -64.4 | -125.4 | -90.0 | -85.6 | -2.3 | .0 | .0 | .0 | .0 |
WACC, % | 13.86 | 13.84 | 13.84 | 13.82 | 13.86 | 13.84 | 13.84 | 13.84 | 13.84 | 13.84 |
PV UFCF | ||||||||||
SUM PV UFCF | -2.0 | |||||||||
Long Term Growth Rate, % | 2.00 | |||||||||
Free cash flow (T + 1) | 0 | |||||||||
Terminal Value | 0 | |||||||||
Present Terminal Value | 0 | |||||||||
Enterprise Value | -2 | |||||||||
Net Debt | -31 | |||||||||
Equity Value | 29 | |||||||||
Diluted Shares Outstanding, MM | 44 | |||||||||
Equity Value Per Share | 0.66 |
What You Will Get
- Real BDTX Financial Data: Pre-filled with Black Diamond Therapeutics’ historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See Black Diamond Therapeutics’ intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Customizable Clinical Parameters: Adjust vital inputs such as patient demographics, treatment efficacy, and trial duration.
- Instant DCF Analysis: Provides real-time calculations for intrinsic value, NPV, and additional financial metrics.
- Industry-Leading Precision: Leverages Black Diamond Therapeutics' (BDTX) actual financial data for accurate valuation results.
- Simplified Scenario Testing: Easily explore various assumptions and assess different outcomes.
- Efficiency Booster: Avoid the hassle of constructing intricate valuation models from the ground up.
How It Works
- Download the Template: Gain immediate access to the Excel-based BDTX DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and other key metrics.
- Instant Calculations: The model will automatically refresh to reflect Black Diamond Therapeutics’ intrinsic value.
- Test Scenarios: Experiment with various assumptions to assess potential changes in valuation.
- Analyze and Decide: Leverage the outcomes to inform your investment or financial analysis.
Why Choose Black Diamond Therapeutics, Inc. (BDTX)?
- Innovative Solutions: Cutting-edge therapies that target genetic drivers of disease.
- Scientific Expertise: Backed by a team of leading scientists and researchers in the field.
- Patient-Centric Approach: Focused on developing treatments that improve patient outcomes.
- Strong Pipeline: Robust portfolio of drug candidates in various stages of development.
- Proven Track Record: Committed to delivering results that meet the highest standards of quality.
Who Should Use This Product?
- Pharmaceutical Students: Explore drug development processes and apply them using real-world data.
- Researchers: Integrate cutting-edge models into studies or academic projects.
- Investors: Evaluate your investment strategies and assess the potential of Black Diamond Therapeutics, Inc. (BDTX).
- Market Analysts: Enhance your analysis with a customizable financial model tailored for biotech companies.
- Healthcare Entrepreneurs: Understand how biotech firms like Black Diamond Therapeutics, Inc. (BDTX) are evaluated in the market.
What the Template Contains
- Preloaded BDTX Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.